Richard Kurupi

1.1k total citations
9 papers, 432 citations indexed

About

Richard Kurupi is a scholar working on Molecular Biology, Neurology and Oncology. According to data from OpenAlex, Richard Kurupi has authored 9 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 5 papers in Neurology and 4 papers in Oncology. Recurrent topics in Richard Kurupi's work include Neuroblastoma Research and Treatments (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and HER2/EGFR in Cancer Research (2 papers). Richard Kurupi is often cited by papers focused on Neuroblastoma Research and Treatments (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and HER2/EGFR in Cancer Research (2 papers). Richard Kurupi collaborates with scholars based in United States and Japan. Richard Kurupi's co-authors include Carlos L. Arteaga, Philip Owens, Rebecca S. Cook, Luis J. Schwarz, Mikhail G. Dozmorov, Todd W. Miller, Justin M. Balko, Henry Gómez, Anthony C. Faber and Neil E. Bhola and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Science Translational Medicine.

In The Last Decade

Richard Kurupi

9 papers receiving 431 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Kurupi United States 9 285 151 143 114 67 9 432
Anja Kafka Croatia 13 315 1.1× 125 0.8× 120 0.8× 77 0.7× 63 0.9× 24 536
Curt J. Essenburg United States 9 180 0.6× 76 0.5× 149 1.0× 106 0.9× 61 0.9× 17 413
Woody Han United States 6 188 0.7× 52 0.3× 141 1.0× 77 0.7× 22 0.3× 8 345
Robert Cozens Switzerland 2 330 1.2× 126 0.8× 142 1.0× 56 0.5× 18 0.3× 3 475
Elizabeth C. Xu Germany 6 177 0.6× 95 0.6× 130 0.9× 97 0.9× 36 0.5× 6 374
Estelle Daudigeos‐Dubus France 11 161 0.6× 72 0.5× 102 0.7× 89 0.8× 90 1.3× 19 332
L. Adam United States 9 279 1.0× 106 0.7× 213 1.5× 102 0.9× 48 0.7× 10 544
Katelyn N. Nelson United States 10 366 1.3× 79 0.5× 95 0.7× 40 0.4× 32 0.5× 14 488
Anni Laine Finland 5 274 1.0× 60 0.4× 178 1.2× 55 0.5× 21 0.3× 6 392
Tambudzai Shamu United States 6 246 0.9× 101 0.7× 74 0.5× 293 2.6× 46 0.7× 7 506

Countries citing papers authored by Richard Kurupi

Since Specialization
Citations

This map shows the geographic impact of Richard Kurupi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Kurupi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Kurupi more than expected).

Fields of papers citing papers by Richard Kurupi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Kurupi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Kurupi. The network helps show where Richard Kurupi may publish in the future.

Co-authorship network of co-authors of Richard Kurupi

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Kurupi. A scholar is included among the top collaborators of Richard Kurupi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Kurupi. Richard Kurupi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Cai, Jinyang, Sheeba Jacob, Richard Kurupi, et al.. (2022). High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell Reports. 40(4). 111095–111095. 10 indexed citations
2.
Krytska, Kateryna, Timothy L. Lochmann, Renata Sano, et al.. (2021). Venetoclax-based Rational Combinations are Effective in Models of MYCN -amplified Neuroblastoma. Molecular Cancer Therapeutics. 20(8). 1400–1411. 13 indexed citations
3.
Floros, Konstantinos V., Jinyang Cai, Sheeba Jacob, et al.. (2021). MYCN -Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis. Cancer Research. 81(7). 1896–1908. 104 indexed citations
4.
Heisey, Daniel A.R., Sheeba Jacob, Timothy L. Lochmann, et al.. (2021). Pharmaceutical Interference of the EWS-FLI1–driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma. Molecular Cancer Therapeutics. 20(10). 1868–1879. 11 indexed citations
5.
Floros, Konstantinos V., Sheeba Jacob, Richard Kurupi, et al.. (2021). Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. Cell Death and Disease. 12(2). 179–179. 14 indexed citations
6.
Lochmann, Timothy L., Konstantinos V. Floros, Richard Kurupi, et al.. (2021). Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN -amplified neuroblastoma. Proceedings of the National Academy of Sciences. 118(13). 18 indexed citations
7.
Lochmann, Timothy L., Krista M. Powell, Jungoh Ham, et al.. (2018). Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. Science Translational Medicine. 10(441). 68 indexed citations
8.
Garrett, Joan T., Cammie R. Sutton, Richard Kurupi, et al.. (2013). Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers. Cancer Research. 73(19). 6013–6023. 72 indexed citations
9.
Balko, Justin M., Luis J. Schwarz, Neil E. Bhola, et al.. (2013). Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer. Cancer Research. 73(20). 6346–6358. 122 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anja Kafka Breakdown of academic impact, for papers by Curt J. Essenburg Breakdown of academic impact, for papers by Woody Han Breakdown of academic impact, for papers by Robert Cozens Breakdown of academic impact, for papers by Elizabeth C. Xu Breakdown of academic impact, for papers by Estelle Daudigeos‐Dubus Breakdown of academic impact, for papers by L. Adam Breakdown of academic impact, for papers by Katelyn N. Nelson Breakdown of academic impact, for papers by Anni Laine Breakdown of academic impact, for papers by Tambudzai Shamu
Rankless by CCL
2026